Dresden Translational Oncology Seminar, Prof. Rebekka Schneider-Kramann, MD, PhD, Institute for Biomedical Engineering, University Hospital RWTH Aachen

Speaker: Rebekka Schneider-Kramann

Title: Dissecting the role of the microenvironment in the initiation and progression of myeloid neoplasms

Host: Dr. Katja Sockel & Dr. Manja Wobus

Zoom Link

Dr. Rebekka K. Schneider is the director of the Department for Cell and Tumor Biology at RWTH Aachen, Germany and a Principal Investigator at Erasmus MC, Netherlands. She received her M.D. degree from RWTH Aachen University, Germany, in 2007 and her Ph.D. degree from Erasmus MC University, the Netherlands, in 2017. Dr. Schneider is a physician scientist and has a broad background in basic and translational research. Her primary focus is disease-oriented laboratory investigation of clonal myeloid neoplasms, employing a range of genomic technologies as well as classical cellular and molecular biology experimental approaches. She is particularly interested in dissecting the interaction between hematopoietic cells and the bone marrow niche, in both steady state and myeloid neoplasms. Dr. Schneider was a postdoctoral fellow in Benjamin Ebert’s lab and focused on the role of genetic haploinsufficiency in hematopoietic stem cell biology and targeted therapy of del(5q) myelodysplastic syndrome. As an independent investigator, one major achievement of her lab has been the identification of fibrosis-driving cells in primary myelofibrosis (PMF) using genetic fate tracing and single cell technologies in murine models and patient samples. It is the ultimate goal of her research to identify novel therapeutic targets to directly block the cellular and molecular changes occurring in BM fibrosis. Based on her recent findings, a clinical trial for patients with advanced myelofibrosis was initiated and will start recruiting next year.

 Exciting topic or interested in chatting with Rebekka Schneider-Kramann about her research? Then feel free to sign up via email (Karoline.laske@nct-dresden.de) for a short, in-person breakout session thereafter.

Clinicians will be rewarded with one continuing education point (SLÄK).